BIO vs QTRX
BIO: Bio-Rad provides essential tools and services for life science research and clinical diagnostics to help advance scientific discovery and improve patient outcomes. QTRX: Quanterix is a leader in precision biomarker science, combining ultra-sensitive protein detection and spatial biology to advance early disease detection and clinical research.
Side-by-side fundamentals
| Metric | BIO | QTRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $360.40 | $3.21 | |
| Market cap | $10.0B | $152M | |
| P/E as of 2026-10-08 | 43.69 | n/a | |
| Net margin FY2025, SEC XBRL | +29.4% | -77.1% | BIO higher |
| Gross margin FY2025, SEC XBRL | +51.9% | +46.8% | BIO higher |
| Operating margin FY2025, SEC XBRL | +1.8% | -90.4% | BIO higher |
| ROE FY2025, SEC XBRL | +10.2% | -36.2% | BIO higher |
| ROA FY2025, SEC XBRL | +7.2% | -25.6% | BIO higher |
| Debt / equity as of 2026-09-03 | 0.17 | 0.00 | QTRX lower |
| Revenue growth (YoY) as of 2026-09-03 | +1.4% | +6.8% | QTRX higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | +9.6% | QTRX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.92 | 1.84 | |
| 1-year return as of 2026-10-08 close | +19.0% | -46.5% | BIO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.